Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 30, 2014

The Symbol Digit Modalities Test (SDMT) Has Been the Standard Cognitive Measure Used in Multiple Sclerosis (MS) Clinical Trials: How Does It Correlate with Computerized Cognitive Screening Tools? (P4.169)

Myassar Zarif, Mark Gudesblatt, Barbara Bumstead, Marijean Buhse, Lori Fafard, Cynthia Sullivan, Jeffrey Wilken, Glen Doniger, Juskaran Chahda
First published April 9, 2014,
Myassar Zarif
5South Shore Neurologic Associates Patchogue NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Gudesblatt
6South Shore Neurology Assoc. PC Patchogue NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Bumstead
5South Shore Neurologic Associates Patchogue NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marijean Buhse
5South Shore Neurologic Associates Patchogue NY United States
7Stony Brook University Stony Brook NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori Fafard
5South Shore Neurologic Associates Patchogue NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Sullivan
2Neuropsychology Associates of Fairfax Fairfax VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Wilken
1NAF Fairfax VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glen Doniger
3NeuroTrax Corporation Modin Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juskaran Chahda
4New York College of Osteopathic Medicine Old Westbury NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
The Symbol Digit Modalities Test (SDMT) Has Been the Standard Cognitive Measure Used in Multiple Sclerosis (MS) Clinical Trials: How Does It Correlate with Computerized Cognitive Screening Tools? (P4.169)
Myassar Zarif, Mark Gudesblatt, Barbara Bumstead, Marijean Buhse, Lori Fafard, Cynthia Sullivan, Jeffrey Wilken, Glen Doniger, Juskaran Chahda
Neurology Apr 2014, 82 (10 Supplement) P4.169;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To explore the correlations between SDMT and NeuroTrax computerized cognitive testing domains. BACKGROUND:Cognitive impairment is common in MS patients. Routine cognitive screening in MS care is not common. The SDMT is frequently used in MS clinical trials to measure cognitive impairment, but is not commonly used in routine care. MS impacts cognition domains differently depending upon plaque size, burden, and location. Easily utilized objective cognitive screens are needed to evaluate the cognitive impact of MS independent of EDSS or MRI. SDMT, a single score cognitive measure, does not provide information about individual cognitive domains or the presence/degree of impairment in multiple domains. Computerized cognitive screening tools have recently become available. These tools provide scores for individual cognitive domains. DESIGN/METHODS: Retrospective review of consecutive MS patients referred for cognitive testing in the course of routine clinical care evaluated with both oral version of SDMT & NeuroTrax testing on the same day. RESULTS: 113 MS patients mean age 48.9±11.3yrs, 85% female. Standardized SDMT score (Centofani, 1975 age norms) significantly (p's<.001) correlated with NeuroTrax Global Cognitive Score (GCS; r=.64) and 7 domain index scores: executive function r=.60, memory r=.58, attention r=.56, visual spatial processing r=.47, information processing speed r=.45, motor skill: r=.40 and verbal function r=.35. CONCLUSIONS: The highest correlations were for domains tapped by SDMT. This provides support for the construct validity of this computerized tool. Computerized cognitive testing may provide an easy independent, objective screening tool that taps into broader sets of cognitive domains, giving individual scores for multiple cognitive domains and a global score. By comparison, evaluation with SDMT screening tool provides one cognitive score related to fewer cognitive domains. Additional studies of cognitive screening tools and correlation to previously utilized clinical trial measures are necessary to facilitate widespread acceptance and incorporation of these tools into routine MS care and patient management. Study Supported by: no outside support

Disclosure: Dr. Zarif has nothing to disclose. Dr. Gudesblatt has received personal compensation for activities with Biogen Idec, Medtronic Inc., Teva Neuroscience, Genzyme Corp., Novartis and Sanofi-Aventis Pharmaceuticals Inc. as a consultant and/or speaker. Dr. Bumstead has received personal compensation for activities with Biogen Idec and Teva Neuroscience. Dr. Buhse has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Bayer Pharmaceuticals Corporation, and Questcor. Dr. Buhse has received research support from Bayer Pharmaceuticals Corporation. Dr. Fafard has nothing to disclose. Dr. Sullivan has received personal compensation for activities with Genzyme Corp. as a consultant. Dr. Wilken has received personal compensation for activities with Biogen Idec and Sention, Inc. Dr. Wilken received research support from Biogen Idec and Cephalon, Inc. Dr. Doniger has received personal compensation for activities with NeuroTrax Corp. as an employee. Dr. Chahda has nothing to disclose.

Wednesday, April 30 2014, 7:30 am-11:00 am

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (10)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise